New research suggests that people who come off popular GLP-1 drugs like Wegovy and Mounjaro tend to recover shed pounds much more quickly than those who halt conventional lifestyle plans.
Published data in a prominent medical journal points out that while obese individuals frequently drop about a fifth of their body weight while undergoing treatment, the mass is regained at an average rate of nearly a kilo each month once they quit.
"People buying such medications need to be aware of the danger of fast weight regain when the treatment ends," cautioned researcher Dr. Susan Jebb.
That rate of regain means a reversion to starting weight in about 18 months.
Comparing Treatments
The analysis, which looked at 37 of studies involving over 9,000 of patients, contrasted the outcomes of these new drugs with conventional dieting.
Scientists emphasize that people who lose weight through lifestyle changes alone usually have a less rapid creep back—approximately 0.1 kg a month—once they finish.
The Reason for the Quick Rebound
Nutrition scientists believe the mechanism of the jabs is key to understanding the heightened rebound.
The injections copy a body's own chemical called glucagon-like peptide-1, which moderates hunger.
"Sustained high doses of GLP-1 levels far above than normal might result in the system to generate a reduced amount of its own natural hormone, and could lessen responsiveness to its effects," noted Dr. Adam Collins, a nutrition expert.
"Discontinuation of this medication leads to hunger is uncontrolled, making binge eating a significant risk."
A Lifelong Disease?
Medical guidelines suggest the jabs for people with weight-linked medical conditions, alongside recommended lifestyle changes.
A number of clinicians contend that, given the high risk of relapse, the therapy should be considered life-long.
This perspective is reinforced by pharmaceutical companies, who note that the findings "emphasize the persistent character of obesity," akin to managing diseases like diabetes.
Patient Accounts
Individuals who have discontinued the medication report a intense return of appetite.
"It was like a switch that goes on and I was suddenly ravenous," said an individual.
This difficulty is compounded if patients have not adopted sustainable dietary or behavioural modifications during therapy.
Significant Adoption
Recent estimates suggest that millions of people in the UK have tried these injections in the past year, with demand being substantial.
- Use is higher among females than men.
- The 40s and 50s age group shows the highest level of interest.
- Many obtain the medications through private healthcare rather than the NHS.
Finally, clinicians emphasize that while GLP-1 drugs are effective agents for weight loss, they are not a permanent cure and maintained weight loss likely depends on ongoing behavioural management.
